- Tafasitamab, sold
under the
brand name
Monjuvi, is a
medication used in
combination with
lenalidomide for the
treatment of
adults with
relapsed or refractory...
- Drug User Fee Act (PDUFA) goal date of
August 30, 2020. On July 31, 2020,
Monjuvi (tafasitamab-cxix) was
approved by the U.S. FDA in
combination with lenalidomide...
-
pharmaceutical products,
including Jakafi (ruxolitinib),
Pemazyre (pemigatinib),
Monjuvi (tafasitamab-cxix) ,
Opzelura (Ruxolitinib),
Tabrecta (capmatinib), Olumiant...
-
humanized integrin αIIbβ3
percutaneous coronary intervention Tafasitamab Monjuvi mab
humanized (from mouse) CD19 Y
relapsed or
refractory diffuse large...
- 1702–1708. doi:10.1158/1078-0432.CCR-18-2743. PMID 30413526. S2CID 53249281. "
Monjuvi: FDA
Approved Drugs". US FDA.
Retrieved August 20, 2020. "FDA
grants accelerated...
